PHAT vs PNTG: fair value comparison
Phathom Pharmaceuticals, Inc. and The Pennant Group, Inc. · Updated 2026-10-19
PHAT's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, PNTG currently ranks higher by quality score.
| PHAT | PNTG | |
|---|---|---|
| Verdict | Awaiting full valuation | Fairly valued |
| Last price | $6.92 | $41.87 |
| 12-month range | $6.70–$18.08 | $23.75–$42.48 |
| Rank by discount to fair value | — | #71 of 108 Healthcare |
| Rank by quality score | #206 of 301 Healthcare | #204 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Expanding |
| Revenue growth | — | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Uptrend |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: PHAT fair value analysis · PNTG fair value analysis